Literature DB >> 2470752

Effects of platelet-derived growth factor on phosphorylation of the epidermal growth factor receptor in human skin fibroblasts.

S J Decker1, P Harris.   

Abstract

Heterologous regulation of the epidermal growth factor (EGF) receptor by platelet-derived growth factor (PDGF) was studied in FS4 human skin fibroblasts. The addition of PDGF to FS4 cells inhibited high affinity binding of 125I-EGF and stimulated phosphorylation of the EGF receptor. Phosphopeptide analysis by high performance liquid chromatography revealed that PDGF treatment of cells increased phosphorylation at several distinct sites of the EGF receptor. However, PDGF did not stimulate phosphorylation of threonine 654, a residue previously shown to be phosphorylated when protein kinase C is activated. The tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) also stimulated phosphorylation of the same peptides from the EGF receptor as PDGF, and, in addition, induced phosphorylation of threonine 654. TPA inhibited both high and low affinity 125I-EGF binding by these cells. PDGF treatment of cells had no effect on EGF-dependent, tyrosine-specific autophosphorylation of the receptor, whereas TPA treatment was inhibitory. TPA, but not PDGF, stimulated phosphorylation of a Mr = 80,000 protein, known to be a substrate for protein kinase C, even though PDGF appeared to mediate breakdown of phosphoinositides. These data suggest that regulation of EGF receptor function by PDGF and TPA are distinct in these cells, even though some elements of regulation are shared. The results differ from those previously reported for a human lung fibroblast isolate, indicating that cell type-specific differences may exist in metabolism of the EGF receptor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470752

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells.

Authors:  Thamara J Abouantoun; Robert C Castellino; Tobey J MacDonald
Journal:  J Neurooncol       Date:  2010-06-04       Impact factor: 4.130

2.  Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation.

Authors:  Y Saito; J Haendeler; Y Hojo; K Yamamoto; B C Berk
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

3.  Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation.

Authors:  X Qian; C M LeVea; J K Freeman; W C Dougall; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

4.  p185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases.

Authors:  X L Quian; S J Decker; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

5.  Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.

Authors:  Thamara J Abouantoun; Tobey J MacDonald
Journal:  Mol Cancer Ther       Date:  2009-05-05       Impact factor: 6.261

6.  Systemic sclerosis immunoglobulin induces growth and a pro-fibrotic state in vascular smooth muscle cells through the epidermal growth factor receptor.

Authors:  Monique R Arts; Murray Baron; Nidaa Chokr; Marvin J Fritzler; Marc J Servant
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.